Biggest Manufacturer，Talazoparib tosylate sale（1373431-65-2 ） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

  2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Talazoparib tosylate sale, CAS#, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than45KG in stock, pls check:

Name:Talazoparib tosylate sale

CAS#: 1373431-65-2

Formula: C26H22F2N6O4S 

Exact Mass: 

Molecular Weight: 552.5568 

Elemental Analysis: C, 56.52; H, 4.01; F, 6.88; N, 15.21; O, 11.58; S, 5.80

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Talazoparib tosylate sale Intermediates:

1. Talazoparib tosylate sale Intermediate:4-Amino-6-fluoro-3H-isobenzofuran-1-one

Cas#1207453-91-5

we have more than 55kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

2. Talazoparib tosylate sale Intermediate:(E)-6-fluoro-4-((4-fluorobenzylidene)amino)isobenzofuran-1(3H)-one

Cas#1620153-74-3

we have more than 50kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

3. Talazoparib tosylate sale Intermediate:2-Methyl-2H-[1,2,4]triazole-3-carbaldehyde

Cas#99651-37-3

we have more than 65kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

4. Talazoparib tosylate sale Intermediate:Ethyl7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate

Cas#1207454-57-6

we have more than 54kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

5. Talazoparib tosylate sale Intermediate:Ethyl (2S,3S)-7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate

Cas#1373431-65-2 

we have more than 63kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

REFERENCE:

1: Lesueur P, Chevalier F, El-Habr EA, Junier MP, Chneiweiss H, Castera L, Müller E, Stefan D, Saintigny Y. Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation. Sci Rep. 2018 Feb 26;8(1):3664. doi: 10.1038/s41598-018-22022-4. PubMed PMID: 29483558; PubMed Central PMCID: PMC5826933.

2: Correction: Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2018 Feb 15;24(4):985. doi: 10.1158/1078-0432.CCR-17-3661. PubMed PMID: 29449416.

3: Talazoparib Bests Chemo for Breast Cancer. Cancer Discov. 2018 Feb;8(2):OF3. doi: 10.1158/2159-8290.CD-NB2017-180. Epub 2017 Dec 14. PubMed PMID: 29242215.

4: Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017. PubMed PMID: 29238749; PubMed Central PMCID: PMC5719044.

5: Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S. Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer. Theranostics. 2017 Sep 26;7(17):4340-4349. doi: 10.7150/thno.18563. eCollection 2017. PubMed PMID: 29158830; PubMed Central PMCID: PMC5695017.

6: Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther. 2017 Dec;16(12):2735-2746. doi: 10.1158/1535-7163.MCT-17-0365. Epub 2017 Sep 25. PubMed PMID: 28947502; PubMed Central PMCID: PMC5716902.

7: Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8. Erratum in: Clin Cancer Res. 2018 Feb 15;24(4):985. PubMed PMID: 28790114.

8: Hidau MK, Kolluru S, Palakurthi S. Development and validation of a high-performance liquid chromatography method for the quantification of talazoparib in rat plasma: Application to plasma protein binding studies. Biomed Chromatogr. 2018 Feb;32(2). doi: 10.1002/bmc.4046. Epub 2017 Aug 15. PubMed PMID: 28677821.

9: de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27. PubMed PMID: 28242752; PubMed Central PMCID: PMC5905335.

10: Correction: Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clin Cancer Res. 2017 Feb 15;23(4):1118-1119. doi: 10.1158/1078-0432.CCR-16-2920. PubMed PMID: 28211356.

11: Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget. 2017 Jul 25;8(30):48794-48806. doi: 10.18632/oncotarget.10720. PubMed PMID: 27447864; PubMed Central PMCID: PMC5564725.

12: Wang B, Chu D, Feng Y, Shen Y, Aoyagi-Scharber M, Post LE. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-te trahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59(1):335-57. doi: 10.1021/acs.jmedchem.5b01498. Epub 2015 Dec 23. PubMed PMID: 26652717.

13: Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. Oncotarget. 2015 Dec 22;6(41):43978-91. doi: 10.18632/oncotarget.6287. PubMed PMID: 26539646; PubMed Central PMCID: PMC4791280.

14: Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015 Feb 15;21(4):819-32. doi: 10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1118-1119. PubMed PMID: 25500058; PubMed Central PMCID: PMC4587665.